ENTITY
Jinxin Fertility

Jinxin Fertility (1951 HK)

126
Analysis
Health Care • China
Jinxin Fertility Group is a leading international provider of assisted reproductive services (ARS) and assisted reproductive technology (ART). Its core offerings include In Vitro Fertilization (IVF), Intrauterine Insemination (IUI), egg retrieval, embryo transfer, and genetic screening, alongside a range of women's health services. The company is headquartered in Chengdu, China, and was founded in 1951.
more
•19 Aug 2019 13:59

HK Connect Ideas: Highlight of Hang Seng Quarterly Review (2019-08-16)

In our weekly HK Connect Snippet series, we aim to help our investors understand the flow of southbound trades via the Hong Kong Connect, as...

Logo
631 Views
Share
•05 Aug 2019 11:11

HK IPO Analytics 1H2019: MS and CICC Stand Out

At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
886 Views
Share
•04 Jul 2019 08:15

Last Week in GER Research: Budweiser, CIMC, Jinxin Fertility, 360 Finance, Zhongliang, and AMTD

Below is a recap of the key IPO and placement research produced by the Global Equity Research team. This week we update on the IPO valuation for...

Logo
601 Views
Share
•25 Jun 2019 12:25

Jinxin Fertility Group: First-Day Trading Thoughts

Corrigenda: There is an error in this insight. Please note the correction below. Correction: In the last line of the first paragraph below, "......

Logo
685 Views
Share
•25 Jun 2019 12:19

Jinxin Fertility (锦欣生殖) Post-IPO Trading: Fairly Valued

Jinxin Fertility's IPO was priced at the high end and started trading today. In our earlier note, we argued that the company's fairly at the high...

Logo
699 Views
Share
x